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Abstract: The control of vascular smooth muscle contractility enables regulation of blood 
pressure, which is paramount in physiological adaptation to environmental challenges. 
Maintenance of stable blood pressure is crucial for health as deregulation (caused by high or 
low blood pressure) leads to disease progression. Vasotone is principally controlled by the 
cyclic nucleotide dependent protein kinases A and G, which regulate intracellular calcium 
and contractile protein calcium sensitivity. The classical pathways for activation of these 
two kinases are well established and involve the formation and activation by specific cyclic 
nucleotide second messengers. Recently we reported that both PKA and PKG can be 
regulated independently of their respective cyclic nucleotides via a mechanism whereby the 
kinases sense cellular oxidant production using redox active thiols. This novel redox 
regulation of these kinases is potentially of physiological importance, and may synergise 
with the classical regulatory mechanisms. 
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1. Introduction 
The importance of blood pressure is eminently clear in the modern western world where poor diet 
and lifestyle has lead to a dramatic rise in individuals with high blood pressure (hypertension). 
Untreated, this can lead to increased risk of pathological complications including heart attacks, heart 
failure, peripheral artery disease, aortic aneurysms, stroke and kidney failure [1]. To prevent these 
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complications, hypertension should be rapidly diagnosed and treated. Low blood pressure 
(hypotension) can also be detrimental to health, especially when it results in inadequate tissue 
perfusion and end organ damage. This is often the case in patients with sepsis where hypotension is a 
symptom of this disease resulting from bacterial infection [2,3]. Due to the harm of sustained hypo- or 
hypertension, humans have evolved numerous biochemical pathways for regulating blood pressure, 
permitting dynamic changes in blood flow to occur, thus allowing the body to adapt to physical and 
environmental changes. However, these pathways can become disrupted as a result of genetic 
susceptibility and lifestyle factors, leading to loss of blood pressure homeostasis and disease 
progression. Over many years the underlying mechanisms that regulate blood pressure have been 
elucidated, giving us a greater understanding of the biological processes that can lead to dysfunction. 
This increase in knowledge has lead to the development of numerous drugs that can help prevent 
hypertension including angiotensin-converting enzyme (ACE) inhibitors, beta blockers, diuretics, 
calcium channel blockers and angiotensin II receptor antagonists [1]. Although much is known about 
blood pressure regulation, the field is still advancing with the potential for more effective drug targets 
and treatments. Indeed, the discovery that protein kinase A (PKA) and protein kinase G (PKG) are 
oxidant sensors that can regulate blood pressure and cardiac contractility via a novel redox mechanism 
offers the potential for novel drugs that activate these pathways [4,5]. In this article the biochemical 
mechanisms by which PKA and PKG regulate blood pressure and cardiac contractility are discussed, 
with a detailed consideration of the newly discovered redox mechanism by which they can be 
enzymatically regulated. 
Oxidants are emerging as important physiological signalling molecules despite many years of bad 
press, which erroneously labeled them as being purely causative agents in disease progression. This 
turn around in perception is due to the failure of numerous antioxidant trials and the growing discovery 
of proteins and pathways that are oxidatively regulated (the “redoxome”) [6-8]. A great variety of 
redox sensitive proteins have been identified including kinases, phosphatases, transcription factors, ion 
channels, metabolic enzymes, RNA binding proteins, caspases and N-acetyl transferases [9]. Protein 
kinase A and G belong to this sub-population of proteins that can act as oxidative sensors due to their 
ability to be modified and enzymatically regulated by cellular oxidants. These proteins contain 
“reactive” cysteine thiols, which are those stabilised in the deprotonated more reactive thiolate (RS
-) 
form due to their local environment. Close proximity with the basic amino acids arginine or lysine 
lower the pKa of cysteine thiols making them more reactive. These thiols can act as redox sensors by 
undergoing a multitude of different oxidative modifications as summarised in Figure 1, which is 
dependent on the oxidant present and proximity to other reactive thiol containing proteins or 
molecules. This process of protein oxidation can regulate cell signalling by altering protein function 
due to a structural change generated by the distinct shape and charge characteristics of the oxidative 
modification. Many forms of these post-translational oxidative modifications can be readily reversed 
by cellular reducing enzymes such as thioredoxin, peroxiredoxin and glutaredoxin [10], allowing 
dynamic reversible signalling events to occur analogous to that of phosphorylation. 
The generation of the reactive oxygen species superoxide is a continual process due to its formation 
as a by-product of energy metabolism crucial for cellular survival and homeostasis [11,12]. 
Furthermore, there are several non-metabolic enzymes that also generate superoxide as a by-product of 
catalysis, many of which are oxidases that reduce molecular oxygen. A group of enzymes also exist Sensors 2010, 10                                       
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that generate superoxide as a primary product, and are known as NADPH oxidases. These enzymes are 
known to play an important role in both physiological as well as pathological signalling in cell growth, 
migration and tissue inflammation [13]. The superoxide generated by these enzymes can be readily 
converted to the more stable oxidant hydrogen peroxide (H2O2) following reduction by superoxide 
dismutase [14]. This form of ROS acts as a physiological second messenger signalling molecule by 
selectively oxidising target proteins [9]. H2O2 is able to act as a signalling molecule by fulfilling the 
several criteria required for the dynamic regulation of protein function. This includes regulated 
formation of this oxidant in response to specific stimuli, selectivity of target protein oxidation 
(provided by “reactive” cysteine residues only in selected targets), a change in protein function (that 
must be demonstrated experimentally), and rapid reversibility by reducing enzymes, as well as 
localised changes in cellular redox due to compartmentalisation of antioxidants and oxidant-generating 
enzymes. This has been shown to be the case for oxidants generated transiently in response to growth 
factor and cytokine stimulation, where their formation is essential for the full spectrum of signalling 
events they can trigger [15-17]. 
Figure 1. The oxidative post-translational modifications that can form on cysteine 
residues. 
 
2. Regulation of Vascular Smooth Muscle Tone 
The regulation of blood pressure is maintained physiologically by changes in smooth muscle tone. 
Increased relaxation causes vessels to dilate, augmenting the total volume blood capacity, leading to a 
subsequent decrease in pressure within the blood vessel. Substantial characterisation at the molecular 
level has revealed that vascular smooth muscle tone is essentially controlled by the interplay between 
two opposing pathways, with the overall result being dependent on the rate of myosin light chain Sensors 2010, 10                                       
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phosphorylation. The contractile response is calcium dependent and leads to increased myosin light 
chain kinase (MLCK) activity and inhibition of the myosin light chain phosphatase (MLCP) [18]. This 
increases the phosphorylation state of the myosin light chain thereby stimulating its ATPase activity, 
resulting in augmented contraction due to increased cycling of cross-bridges with actin. Several 
circulating factors are known to induce smooth muscle contraction including endothelin-1 [19,20], 
angiotensin II [21], and the alpha1-beta adrenergic receptor stimulators epinephrine and norepinephrine 
[22,23]. Activation of specific receptors on the surface of smooth muscle cells by these ligands leads to 
increased G protein dependent activation of phospholipase C [24]. This enzyme cleaves 
phosphatidylinositol 4,5 bisphosphate (PIP2) to form D-myo-inositol-1,4,5-trisphosphate (IP3), a 
second messenger that increases Ca
2+ release from the sarcoplasmic reticulum (SR) by activating IP3 
receptors (IP3R). This enhances Ca
2+ dependent Ca
2+ entry via opening of transient receptor potential 
channels (TRPs) and SR store-operated Ca
2+ channels [25,26]. This elevated cytosolic Ca
2+ interacts 
with calmodulin forming a complex that activates MLCK, a process which leads to enhanced vascular 
smooth muscle constriction [27]. 
The contractile response of vascular smooth muscle is inhibited by three known converging 
pathways that prevent myofilament cross-bridge cycling to generate smooth muscle relaxation. These 
are the Protein kinase A (PKA), Protein kinase G (PKG) and endothelium derived hyperpolarising 
factor (EDHF) pathways, each of which acts as a vasodilator by decreasing intracellular Ca
2+ in 
vascular smooth muscle cells. This decrease in Ca
2+ concentration leads to inhibition of MLCK and 
activation of MLCP, switching the myosin light chain from the phosphorylated contractile state to the 
dephosphorylated relaxed state. The three known vasodilatory pathways are summarised in Figure 2. 
Figure 2. Three dominant pathways for regulating vascular smooth muscle relaxation. 
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Both PKA and PKG are classically considered to be cyclic nucleotide dependent and require the 
formation of active vasodilators by the endothelium. In the case of PKA, increased prostacyclin (PGI2) 
formation and diffusion from endothelial cells to smooth muscle cells increases the activity of 
adenylate cyclase, which converts adenosine triphosphate (ATP) to  3'-5'-cyclic  adenosine 
monophosphate (cAMP) a direct activator of PKA [28]. For the classical activation of PKG, nitric 
oxide (NO) is generated by nitric oxide synthases (NOS) located in endothelial cells. The signalling 
molecule NO then diffuses into smooth muscle cells where it binds to the haem centre and activates 
soluble guanylate cyclase, an enzyme that converts guanosine triphosphate  (GTP) to  3',5'-cyclic 
guanosine monophosphate (cGMP), a secondary messenger that directly activates PKG [29]. 
Formation of the vasodilator NO in endothelial cells is mediated by shear stress as well as a number 
of biological circulating factors including bradykinin, substance P, acetylcholine, histamine, adenosine 
and thrombin [30,31]. These substances all generate smooth muscle relaxation by binding to G-protein 
coupled receptors on the surface of endothelial cells, which line the inner wall of blood vessels. 
Activation of these receptors induces the production of IP3 by phospholipase C. This secondary 
messenger binds to IP3R on the surface of the endoplasmic reticulum, causing the release of Ca
2+, 
which then binds to calmodulin, forming a complex that stimulates the activity of NOS [30]. This 
enzyme utilises arginine to produce NO and the by-product citrulline. 
Activation of PKG in smooth muscle cells leads to phosphorylation of several targets that regulate 
contractile protein Ca
2+ sensitivity and the intracellular Ca
2+ concentration. This includes direct 
modification of the large conductance Ca
2+-activated K
+ channel (BKca) on the cell membrane, 
increasing its open probability [32,33]. Increased cellular export of K
+ cation causes membrane 
hyperpolarisation, closing voltage-dependent Ca
2+ channels, decreasing the total Ca
2+ influx. Another 
source of intracellular Ca
2+ is that extruded from the SR with the influx and efflux being regulated by 
several specific membrane Ca
2+ handling proteins. This includes the Ca
2+ importing pump SERCA, 
which is normally inhibited by the associated protein phospholamban. Phosphorylation of 
phospholamban by PKG removes the brake on SERCA activity, increasing the import of Ca
2+ into  
the SR [34,35]. 
Most contractile agonists work by activating smooth muscle Gq-coupled receptors and 
phospholipase C to increase IP3 production. This second messenger stimulates Ca
2+ release from the 
SR, which activates MLCK. PKG is able to inhibit this pathway by phosphorylating the IP3  
receptor-associated PKG-substrate (IRAG), which when modified inhibits IP3 stimulated SR Ca
2+ 
release by the IP3R [36-38]. There is also some evidence that PKG can inhibit the IP3R by direct 
phosphorylation [39]. Furthermore, the production of IP3 by phospholipase C is suppressed by   
PKG-dependent phosphorylation of the regulator of G-protein signalling 2 (RGS2) [40,41]. When 
RGS2 is phosphorylated by PKG it increases the GTPase activity on Gq, decreasing the GTP that is 
required for phospholipase C activation. 
The activation of MLCP is crucial for smooth muscle relaxation, which is maintained by   
PKG-dependent target phosphorylation. Essentially PKG is able to do this by preventing the 
inactivation of MLCP by Rho kinase (ROCK). The activator of ROCK, rhoA is directly 
phopshorylated by PKG increasing its affinity for the guanine
 dissociation inhibitor (GDI), preventing 
the translocation of RhoA to the membrane which is required for activation [42,43]. Another target of 
phosphorylation by PKG is Ser-695 on the myosin phosphatase target subunit 1 (MYPT1) of the Sensors 2010, 10                                       
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MLCP, which prevents ROCK from phosphorylating the adjacent Thr-696 that normally leads to 
enzyme inactivation [44,45]. An additional target of PKG is the small heat shock protein HSP20 which 
induces smooth muscle relaxation and blocks agonist induced constriction [46,47]. HSP20 acts as a 
late-phase signalling molecule, binding to actin when phosphorylated by PKG, which likely prevents 
reorganisation of the actin cytoskeleton that is required for constriction. 
Figure 3. The biochemical targets of PKG in vascular smooth cells that mediate 
vasorelaxation. 
 
The enzymes PKA and PKG share much homology in terms of structure especially around the 
catalytic site, giving both kinases the ability to phosphorylate several common substrates. Variations in 
targets between the two kinases is likely due to differential localisation controlled by binding proteins, 
such as A-kinase anchoring proteins (AKAPs) for PKA and G-kinase anchoring proteins for PKG 
(GKAPs) [48-51]. These anchoring proteins localise the kinases to the vicinity of their substrates, 
allowing controlled selective signalling events to occur. Like PKG, PKA activation also induces 
smooth muscle relaxation [52]. However the mechanism for PKA has not been characterised to the 
same extent to that of PKG. Nevertheless several shared substrates have been identified between the 
two kinases which mediate vasodilation. These include phospholamban [53,54], HSP20 and RhoA 
[46,55,56], with some evidence of MYPT1 also being a target of PKA [57]. 
A third biochemical process that mediates vascular dilation is the formation of EDHF, which as the 
name suggests is produced in endothelial cells and generates relaxation in smooth muscle cells by 
hyperpolarising the membrane. The synthesis of EDHF is stimulated by the neurotransmitter 
acetylcholine, the small peptide bradykinin, shear stress and a number of other agonists. The role of 
EDHF in regulating blood pressure is as prominent as the PKG and PKA pathways, with deficiency in Sensors 2010, 10                                       
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EDHF signalling contributing to several cardiovascular pathologies including hypertension, chronic 
renal failure, and diabetes [58,59]. The reason for this is likely due to EDHF being particularly 
effective in modulating vascular tone in an endothelium-dependent manner in small resistance vessels, 
which are the major determinants of systemic blood pressure [60-62]. The mechanism by which EDHF 
induces vasodilation is independent of NO and PGI2 with its exact identity remaining unknown [58]. 
However, several potential candidates for EDHF have been proposed including K
+, epoxyeicosatrienoic 
acid (EET), H2O2 and electronical communication through the gap junctions [59,63-65]. Evidence exists 
for each being an EDHF but its identity (although it likely has multiple components) remains 
controversial due to substantial contradictory evidence. The failure to get consistent results between 
different research groups is likely due to variations in the experimental conditions or the use of different 
vessel types that may have differential responses to each proposed EDHF. 
The classical view of blood pressure regulation involves a summation of three primary pathways 
that are coordinated in a complex manner as outlined above. These pathways are independently 
regulated but also integrate to generate a net blood pressure. Each pathway can be dynamically 
regulated by changes in circulating factors and in some cases shear stress with responses varying 
depending on the specifics of the diverse physiological/pathological conditions and between different 
vessel types. The inhibition of EDHF signalling or knockdown of PKG causes dysfunctional regulation 
of blood pressure, which highlights the importance of each pathway in controlling vasotone [58,59,66]. 
The significance of PKA signalling in regulating blood pressure has not been characterised to the same 
extent and therefore its overall contribution is not so apparent. Our discovery of a novel mode for the 
oxidative regulation of the PKA and PKG pathway (as summarised in section 4) further adds to the 
complexity and potential dynamic regulation of blood pressure. This discovery highlights the potential 
for cross-talk between these pathways and possible integration of the EDHF phenomenon into the 
PKG signalling cascade.  
 
3. Regulation of Cardiac Contractility 
 
As with the control of vascular smooth muscle cell contraction and relaxation, regulation of cardiac 
contractility is also dependent on intracellular calcium. Increased Ca
2+ influx into cardiac cells 
stimulates the myofilaments to generate more force during contraction due to greater cross-bridge 
cycling. This process is carefully maintained to ensure adequate myocardial contractile performance 
and is primarily regulated by the autonomic nervous system, allowing the heart to adapt and function 
effectively during various environmental challenges [67]. This includes regular daily activities such as 
aerobic exercise and even during simple tasks such as the body assuming an upright position. These 
are often termed the “flight or fight” response and are characteristic of a change in heart rate, force of 
cardiac contractility and the rate of subsequent cardiac relaxation. Stimulation of the sympathetic 
nervous system leads to release of β-adrenergic receptor agonists from activated sympathetic nerves 
into the circulatory system [68]. The stimulation of β-adrenergic receptors in the heart by these 
agonists activates adenylate cyclase (AC) via the stimulatory G-protein (GSα), this increases cAMP 
production and subsequent PKA activation [68,69].  
The heart is a large pump that generates the force required for propelling the blood through the 
circulatory system by contracting and relaxing in a rhythmic fashion (sinus rhythm). The initiation of Sensors 2010, 10                                       
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cardiac muscle contraction is controlled by the sinoatrial node (cardiac pacemaker) [70], which is 
located in the upper wall of the right atrium and initiates atrial contraction by generating a wave of 
electrical excitation (action potential). This electrical stimulation moves through the atria until it 
reaches the atrioventricular node, situated in specialised tissue between the atria and the ventricles of 
the heart (posteroinferior region of the interatrial septum). The impulse is delayed at this node to allow 
enough time for the atria to eject its blood into the ventricles first, before the ventricles contract. After 
the delay the wave of stimulation is transmitted through the bundles of His and back up the Purkinje 
fibres causing contraction of the ventricles. The process from electrical excitation of the myocyte to 
contraction of the heart is known as cardiac excitation–contraction coupling. Each heart muscle cell 
contracts in unison when stimulated by the action potential [71]. In the unstimulated (resting potential) 
state the muscle cell sarcolemma (plasma membrane) is polarised. This is due to large negatively 
charged intracellular proteins and amino acids and the balance between K
+ inside and Na
+ outside the 
cell. This gives the sarcolemma a negative charge on the inside with respect to the outside. During an 
action potential opening and then rapid closure of Na
+ channels on the sarcolemma leads to 
depolarisation and activation of voltage-dependent Ca
2+ channels, including the L-type Ca
2+ channel 
located in the T-tubular membrane. This increases the influx of Ca
2+ and the inward Ca
2+ current (ICa), 
which contributes to the action potential plateau. The elevated Ca
2+ binds to and activates the 
ryanodine receptors (RyRs), which are ligand-gated channels located on the SR membrane. This 
enhances the release of Ca
2+ from the SR and is known as Ca
2+-induced Ca
2+ release. This amplified 
intracellular Ca
2+ binds to cardiac troponin C (cTnC) triggering the constriction of myofilament 
proteins. The removal of Ca
2+ from the cytosol allows dissociation of Ca
2+ from troponin C and 
subsequent myofilament relaxation [72]. This occurs during repolarisation of the sarcolemma due to 
opening of K
+ channels, increasing the export of K
+, closing the voltage-dependent Ca
2+ channels. The 
intra and extracellular Na
+ and K
+ concentrations are returned to resting state by the sarcolemmal 
Na
+/K
+-ATPase (NKA). The extrusion of Ca
2+ from the cytosol is mediated by the SR Ca
2+-ATPase 
(SERCA), the sarcolemmal Na
+/Ca
2+ exchange (NCX1) and sarcolemmal Ca
2+-ATPase. Increased 
cytosolic Ca
2+ is sequestered into the SR Ca
2+ store by SERCA, replacing that lost from the RyR 
during an action potential [73]. Extrusion of Ca
2+ from the cell is mediated by NCX1, which is 
generally believed to import three Na
+ ions for every Ca
2+ ion extruded and is regulated by both 
transmembrane voltage and Na
+ and Ca
2+ concentration gradients [74]. This exchanger can work both 
in forward and reverse mode with evidence suggesting during the plateau phase of an action potential 
it extrudes Na
+ and imports Ca
2+, with it flipping to the forward mode during repolarisation [75-77]. A 
second mechanism that has a minor role in the export of Ca
2+ from the cell is the sarcolemmal Ca
2+-
ATPase, which hydrolyses ATP to transport Ca
2+ out of the cell [78].  
Phospho-regulation by PKA of several key Ca
2+ handling proteins increases cardiac contractility 
(see Figure 4). This includes the increased import and export of Ca
2+ from the SR. One of the targets of 
PKA located on the SR is the Ca
2+ channel the ryanodine receptor. This protein is a tetramer 
comprised of four type 2 RyR polypeptides (RyR2) and four FK506 binding proteins (FKBP12.6). The 
activity of this protein is regulated by intracellular Ca
2+ with low concentrations (M) increasing 
activity and high concentrations (mM) being inhibitory [79]. PKA is able to regulate the open 
probability of RyR by phosphorylating RyR2 polypeptides causing them to dissociate from FKBP12.6. 
This increases the open probability and enhances sensitivity to Ca
2+-induced activation. With the Sensors 2010, 10                                       
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overall effect being the augmented export of Ca
2+ from the SR following an action potential [80]. 
Another SR Ca
2+ handling protein that is regulated by PKA is the SERCA pump. The activity of this 
protein is inhibited by its interaction with the 52 amino acid membrane protein phospholamban. 
Phosphorylation of phospholamban at Ser-16 by PKA attenuates its ability to inhibit the SERCA pump 
[81]. This increases the import of Ca
2+ into the SR, which enhances the rate of relaxation and also 
results in augmented release of Ca
2+ following a second action potential from the enhanced Ca
2+ SR 
store. The influx of extracellular Ca
2+ is also enhanced by PKA through the regulation of sarcolemmal 
Ca
2+ handling proteins. This includes the L-type Ca
2+ channel that is phosphorylated by PKA at the 
1C subunit at Ser1928 and the 2 subunit at Ser-478 and Ser-479, which increases the open 
probability of this channel [82,83]. The activity of the Na/K ATPase is also regulated by PKA. 
Phosphorylation of the associated protein phospholemman (PLM) at Ser-68 by PKA relieves its ability 
to inhibit the NKA, increasing the cellular export of Na
+ [84].This is negatively inotropic which is 
contradictory to the effect that is normally associated with PKA activation. However it is believed that 
increased activity of the NKA by PKA is important in preventing Ca
2+ overload in response to -
stimulation by limiting the rise in intracellular Na
+ that may help maintain the NCX1 in its forward 
mode. This is supported by transgenic mice that do not express PLM in which β-adrenergic stimulation 
does not
 activate NKA and that the amplitude of Ca
2+ transients is significantly
 higher than for wild-
types. The SR Ca
2+ content was also increased in PLM knockout mice and was associated with an 
increased propensity for spontaneous
  Ca
2+ transients and contractions in these animals [85]. 
Furthermore it has been suggested that NKA activation by PKA may also prevent diastolic dysfunction 
and protect against arrhythmias although further research is required to substantiate these claims. 
As well as Ca
2+ handling proteins, PKA also has several targets that are myofilament proteins 
required for cardiac constriction. Cardiac troponin I (cTnI) is a target with residues 23 and 24 being 
phosphorylated. This increases the rate of cardiac relaxation by enhancing the rate at which Ca
2+ is 
dissociated from cTnC without effecting maximum actomysoin ATPase activity [86-88].  Another 
myofilament target of PKA is the cardiac myosin binding protein C (cMyBP-C). Using transgenic 
mice that have a non-phosphorylatable form of cMyBP-C it was found that basal phosphorylation is 
necessary for maintaining thick-filament orientation, dynamic regulation, and contractile mechanics [89]. 
This basal phosphorylation of cMyBP-C is likely maintained by PKA activity preventing cardiac 
dysfunction. In addition, phosphorylation of this myofilament protein has recently been shown to play 
a role in enhancing cardiac contractility by accelerating crossbridge kinetics [90]. 
Activation of PKG is also known to regulate cardiac contractility. However, its role has not been 
characterised to the same extent as PKA and is seen as somewhat controversial due to the biphasic 
effect of NO donors on the cardiac inotropy. Nevertheless a recent publication has put into perspective 
the likely effect of direct PKG stimulation on cardiac contractility. It is reported that NO donor 
concentrations that induce protein oxidation (S-nitrosylation) and not PKG activation increase cardiac 
contractility. In contrast, concentrations of NO donor that stimulate PKG, or the use of cGMP-analogs 
as direct activators, lead to decreased contractility [91]. These findings are supported by PKGI 
knockout mice that do not have a change in force of contraction after treatment with a cGMP-analog 
PKG activator. In contrast the wild-type mouse shows a reduction in force of contraction following 
PKG activation [92].  The ability of PKG to decrease contractility is likely through its ability to 
increase SERCA activity which will lower free cytosolic Ca
2+
 [93,94], and the phosphorylation of cTnI Sensors 2010, 10                                       
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that will decrease the sensitivity of cTnC for Ca
2+ [95,96]. Both of these proteins are substrates for 
PKA and PKG but the reason for the difference in contractility between these kinases is that unlike 
PKA, PKG does not also simultaneously enhance the positively inotropic SR release of Ca
2+ or 
extracellular influx of Ca
2+. Furthermore, PKG is able to reduce the cellular intake of Ca
2+ by directly 
inhibiting voltage activated Ca
2+ channels. This is substantiated by experiments demonstrating that 
activation of PKG causes inhibition of L-type Ca
2+ channel whole cell current after phosphorylation of 
the ß2a subunit at Ser496 [97]. This is substantiated by previous findings in which mice overexpressing 
PKGI had increased inhibition of L-type Ca
2+ channels compared to wild-type [98]. 
Figure 4. The biochemical targets of PKA and PKG in cardiac myocytes that regulate 
cardiac contractility. 
 
 
4. Redox Regulation of PKAI and PKG1 Activity 
 
As mentioned in the introduction many proteins can act as redox sensors and signal transducers by 
being functionally regulated by cysteine oxidation. We undertook a project to identify such proteins 
with the aim of finding those that specifically formed inter-protein disulphide complexes, an 
anticipated oxidation product [99]. The rationale being that redox signalling may be mediated by 
oxidants that can induce inter-protein disulphides, a structural modification that has the propensity to 
alter enzyme function. Detection of these disulphide bound complexes was achieved using a diagonal 
gel electrophoresis technique. In brief, samples were prepared from ventricular myocytes exposed to 
control conditions or oxidative stress with the thiol-selective oxidant diamide. Cells were reconstituted Sensors 2010, 10                                       
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in non-reducing SDS sample buffer and resolved by SDS-PAGE. Once complete an entire   
protein-containing lane was carefully excised and placed horizontally on top of a fresh gel and 
resolved under reducing conditions. Any proteins that did not form disulphide complexes run at the 
same molecular weight as during the first separation, forming a diagonal across the gel after being 
resolved. Proteins that formed a disulphide now run at a lower molecular weight than in the first run 
and therefore resolve away from the diagonal plane in each gel. Treatment of hearts with diamide 
increased the number of proteins running off of the diagonal plane in gels stained with colloidal 
Coomassie blue, representing proteins that formed disulphide bonds. These protein spots were 
carefully extracted from each gel and analysed using mass spectrometry analysis. Several proteins 
were identified including the type I regulatory subunit of protein kinase A (PKA-RI). Due the 
importance of this protein in the regulation of the cardiovascular system, as highlighted above, we 
investigated the significance of disulphide bond formation on PKAI enzyme function [5]. This kinase 
was already thought to contain two constitutive disulphides between each RI subunit [100], which run 
anti-parallel to each other. Thus, cysteine 17 on one subunit forms a disulphide with cysteine 38 on the 
other, and this occurs twice in each dimer. We hypothesised that these disulphides occurred under 
oxidising conditions and were not present under basal, reducing conditions present intracellularly. To 
assess this, we ran non-reducing SDS-PAGE gels using homogenates from hearts perfused with 
varying concentrations of H2O2. When these samples were immunostained following Western blotting 
with a PKA-RI antibody most of the protein was monomeric in the controls, with a concentration-
dependent increase in disulphide dimer after H2O2 treatment. The disulphide reducing agent 2-
mecaptoethanol confirmed that the dimer was the result of disulphide formation as it reduced this 
complex back to its monomeric form.  
To determine the functional significance of this oxidative modification on PKA activity the 
contractility of isolated adult rat ventricular myocytes was measured. In the presence of H2O2 myocyte 
contractility was augmented, which could be inhibited by the addition of the PKA inhibitor, H89. This 
enhanced contractility was accompanied by an increase in phosphorylation of the PKA substrates 
phospholamban and troponin I, a process which was also sensitive to H89 inhibition. Furthermore, this 
apparent activation of PKA by oxidation was independent of cAMP. This was evident from a specific 
fluorescence based assays for cAMP, showing that H2O2 treatment did not augment formation of this 
cyclic nucleotide. Together this data suggested that oxidation can directly enhance the activity of 
PKAI independent of cyclic nucleotide stimulation. We hypothesised that this augmentation of PKAI 
substrate phosphorylation following oxidation may be mediated by the kinases ability to interact with 
its binding partners the AKAPs [48,49]. The rational being that formation of redox sensitive 
disulphides located in the known region where the kinase interacts with its AKAPs may increase 
binding affinity, and therefore enhance PKAI localisation to its substrates. This was substantiated by 
the discovery that oxidation of PKA-RI increased its affinity for the AKAP -myosin heavy chain. 
This binding protein likely increases localisation of PKAI to its known myofilament substrates, 
troponin I and myosin binding protein C. Recently the ability of disulphide bond formation in PKA-RI 
to enhance its affinity for AKAPs has been further substantiated using fluorescence anisotropy 
experiments. It was shown that mutation of either of the redox sensitive cysteines (so it cannot form a 
disulphide) decreased the enzymes ability to bind to D-AKAP2 compared to the wild-type   
protein [101]. Sensors 2010, 10                                       
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The discovery that PKAI could be enzymatically regulated by oxidation independent of cyclic 
nucleotide stimulation lead us to speculate that PKG1may also be redox sensitive. The rational being 
that both kinases share similar structural homology and also a single constitutive disulphide within the 
N-terminal dimerisation domain of PKG1 has been identified [102]. Western blot analysis of hearts 
perfused using the Langendorff technique with H2O2 highlighted mostly monomer in controls and a 
concentration dependent increase in PKG1 dimer formation which mirrored that of PKA-RI [4]. In 
hearts perfused with H2O2 there was a substantial time dependent decrease in perfusion pressure 
analogous to that of an NO donor. We speculated that this decrease in perfusion pressure by H2O2 may 
be due to activation of PKG1 by direct oxidation. We tested this hypothesis by measuring tension in 
aortic rings as readout of vascular tone. The use of the PKG inhibitor Rp-8-Br-cGMPs and the 
guanylate cyclase inhibitor ODQ blocked NO donor mediated vessel dilation. However, H2O2 induced 
vessel relaxation was only blocked by the PKG inhibitor, supporting an oxidative cyclic nucleotide 
independent mechanisms for PKG1 activation. Michaelis Menten kinetic analysis of recombinant 
PKG1activity using a radioactivity based kinase assay confirmed that oxidation can directly activate 
PKG1 independent of cGMP, by increasing the enzyme affinity for its substrate by approximately 7-
fold. Mutation in PKG1 of the redox sensitive cysteine 42 to a charge conserved serine residue 
removed the ability of this kinase to be activated and to disulphide dimerise in response to H2O2 
treatment. This is compelling evidence demonstrating that oxidation of cysteine 42 is crucial for redox 
activation of PKG1. The mechanism for oxidative activation of PKAI and PKG1 is summarised in 
Figure 5, which also includes the NMR structure for the N-terminus of each kinase with the redox 
sensitive disulphides highlighted in yellow [103,104]. 
To some researchers the use of exogenous H2O2 is sometimes seen as being a non-physiological 
means of investigating protein oxidation. To overcome the potential skepticism associated with using 
exogenous oxidants we treated rat aortic smooth muscle cells with physiologically relevant 
concentrations of insulin, a known mediator of endogenous oxidant formation [105,106]. The use of 
insulin was sufficient to induce a robust detectible increase in PKG1 disulphide dimerisation, 
demonstrating that our findings were not an artifact of using exogenous H2O2. Furthermore it was 
found that transnitrosylating species of NO (CysNO) are also able to mediate the formation of PKG1 
and PKA-RI disulphide dimers [107]. A finding that coincided with increased relaxation in vessels 
treated with CysNO, which was cyclic nucleotide independent. With the stimulation of PKA by 
oxidation, one would expect an increase in cardiac contractility that is normally associated with 
activation of this kinase. However this is not the case when perfusing with H2O2, which has very little 
effect on cardiac contractility. As discussed in this article PKA and PKG have opposite effects on the 
cardiac ionotropy due to their ability to differentially regulate intracellular Ca
2+. Based on this 
evidence we hypothesised that simultaneous activation of PKG may override the effect of PKA 
stimulation. We tested this theory using isoprenaline to activate PKA and enhance cardiac 
contractility. The addition of an NO donor to stimulate PKG activity reversed the ionotropic effect of 
isoprenaline, demonstrating that PKG can override PKA induced elevations in contractility. It is 
important to consider that in perfusion experiments, using an exogenous oxidant will simultaneously 
activate both kinases due to global cellular oxidation. During a physiological or pathological scenario 
change in oxidant formation are likely to occur in localised areas of the cell within close proximity to Sensors 2010, 10                                       
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the enzymes that generate them, such as superoxide dismutase. This could allow differential changes in 
oxidant mediated contractility to occur due to stimulation of select pools of PKA or PKG1. 
Figure 5. (a) The NMR structure of the N-terminal dimerisation domain of PKG1 
including the redox sensitive disulphide bond (b) The NMR structure of the dimerisation 
domain of the type I alpha regulatory subunit of protein kinase A including the redox 
sensitive disulphides (c) The basic mechanism of how oxidants (H2O2 or nitrosylation 
species of NO (SNO)) can augment PKG1 activity and enhance the affinity of PKAI for 
it binding partners, the AKAPs. 
 
 
The potential physiological importance of oxidative activation of PKG1 or PKAI may tie in with 
EDHF signalling, with substantial evidence in favor of the oxidant H2O2 being at least a component of 
EDHF. This is supported by reports showing that the application of exogenous H2O2 can lead to 
relaxation in a number of blood vessels [108-110]. The possibility that H2O2 acts as a component of 
EDHF is further supported by NO- and prostanoid-independent relaxation being blocked by catalase, 
which selectively breaks down H2O2 [111,112]. In addition, aminotriazole (which inhibits catalase) 
relieves the inhibitory effect of catalase on EDHF-mediated relaxation [113]. The production of H2O2 
has also been directly measured in porcine coronary microvessels using electron spin resonance 
imaging following bradykinin treatment (which is known to generate EDHF) [111,112,114]. This 
intervention induced a detectable increase in the formation of H2O2 and vessel relaxation, both of 
which were inhibited by catalase. In theory oxidative activation of PKG1 should mimic the effect of 
EDHF by increasing the open probability of BKCa channels after phosphorylation, leading to increased 
hyperpolarisation and vascular relaxation [32,33]. Therefore the oxidative mechanism for PKG1 or 
PKAI activation provides a potential molecular explanation for the EDHF phenomenon. 
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5. Conclusion 
 
The discovery that PKAI and PKG1 are redox sensors and signal transducers that can be regulated 
by cellular oxidants means there needs to be an addition to the well-established models for their 
activation. These findings highlight the potential for oxidants to regulate both vasotone and the cardiac 
inotropic environment. However, further characterisation to determine the full extent of the 
physiological as well pathological roles of these oxidative mechanisms needs to be undertaken. It is 
tantalising to suggest that EDHF may be an oxidant that can induce vasodilation through direct 
oxidative activation of PKG1 or PKAI. However, this is yet to be determined and will likely require 
the development of sensitive techniques that can determine small variations in PKG1 or PKAI 
oxidation. 
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